Reduced miR-3127-5p expression promotes NSCLC proliferation/invasion and contributes to dasatinib sensitivity via the c-Abl/Ras/ERK pathway

Scientific Reports

Volumn 4, Issue , 2014, Pages

  Sun, Yifeng ^a   Chen, Chang ^a   Zhang, Peng ^a   Xie, Huikang ^b   Hou, Likun ^a   Hui, Zheng ^a   Xu, Yongjie ^a   Du, Qiaoling ^c   Zhou, Xiao ^a   Su, Bo ^b   Gao, Wen ^b  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANGHAI CHEST HOSPITAL   (China)

^c Shanghai First Maternity and Infant Health Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; DASATINIB; MAPK1 PROTEIN, HUMAN; MESSENGER RNA; MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; RAS PROTEIN; THIAZOLE DERIVATIVE; TUMOR MARKER;

ADENOCARCINOMA; AGED; ANIMAL; APOPTOSIS; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CELL ADHESION; CELL MOTION; CELL PROLIFERATION; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; ENZYME IMMUNOASSAY; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LUNG NEOPLASMS; METABOLISM; MORTALITY; MOUSE; NEOPLASM RECURRENCE, LOCAL; NUDE MOUSE; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE; TUMOR INVASION; WESTERN BLOTTING;

ADENOCARCINOMA; AGED; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CELL ADHESION; CELL MOVEMENT; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; MICE; MICE, NUDE; MICRORNAS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-ABL; PYRIMIDINES; RAS PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; THIAZOLES; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84919880787     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep06527     Document Type: Article

References (37)

1. Jemal, A. et al. Global cancer statistics. CA Cancer J Clin 61, 69-90 (2011
2. Siegel, R., Naishadham, D. & Jemal, A. Cancer statistics, 2013. CA Cancer J Clin 63, 11-30 (2013
3. Govindan, R. et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 24, 4539-4544 (2006
4. Seike, M. et al.MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers. Proc Natl Acad Sci U S A 106, 12085-12090 (2009
5. Garofalo, M. et al. miR-221 & 222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell 16, 498-509 (2009
6. Skrzypski, M., Dziadziuszko, R. & Jassem, J.MicroRNA in lung cancer diagnostics and treatment. Mutat Res 717, 25-31 (2011
7. Catuogno, S. et al.miR-34c may protect lung cancer cells from paclitaxel-induced apoptosis. Oncogene 32, 341-351 (2013
8. Bandi, N. & Vassella, E. miR-34a and miR-15a/16 are co-regulated in non-small cell lung cancer and control cell cycle progression in a synergistic and Rbdependent manner. Mol Cancer 10, 55 (2011
9. Corney, D. C., Flesken-Nikitin, A., Godwin, A. K., Wang, W. & Nikitin, A. Y. MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth. Cancer Res 67, 8433-8438 (2007
10. Stark, M. S. et al. Characterization of the Melanoma miRNAome by Deep Sequencing. PLoS One 5, e9685 (2010
11. Dannemann, M., Nickel, B., Lizano, E., Burbano, H. A. & Kelso, J. Annotation of primate miRNAs by high throughput sequencing of small RNA libraries. BMC Genomics 13, 116 (2012
12. Persson, H. et al. Identification of new microRNAs in paired normal and tumor breast tissue suggests a dual role for the ERBB2/Her2 gene. Cancer Res 71, 78-86 (2011
13. Janowska-Wieczorek, A. et al. Bcr-abl-positive cells secrete angiogenic factors including matrix metalloproteinases and stimulate angiogenesis in vivo in Matrigel implants. Leukemia 16, 1160-1166 (2002
14. Nakamura, Y., Grumont, R. J. & Gerondakis, S. NF-kappaB1 can inhibit v-Ablinduced lymphoid transformation by functioning as a negative regulator of cyclin D1 expression. Mol Cell Biol 22, 5563-5574 (2002
15. Mayerhofer, M., Valent, P., Sperr, W. R., Griffin, J. D. & Sillaber, C. BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin. Blood 100, 3767-3775 (2002
16. Noy, P., Gaston, K. & Jayaraman, P. S. Dasatinib inhibits leukaemic cell survival by decreasing PRH/Hhex phosphorylation resulting in increased repression of VEGF signalling genes. Leuk Res 36, 1434-1437 (2012
17. Renshaw, M. W., Lewis, J. M. & Schwartz, M. A. The c-Abl tyrosine kinase contributes to the transient activation of MAP kinase in cells plated on fibronectin. Oncogene 19, 3216-3219 (2000
18. Scholzen, T. & Gerdes, J. The Ki-67 protein: from the known and the unknown. J Cell Physiol 182, 311-322 (2000
19. Sirvent, A., Benistant, C. & Roche, S. Cytoplasmic signalling by the c-Abl tyrosine kinase in normal and cancer cells. Biol Cell 100, 617-631 (2008
20. Ganguly, S. S. & Plattner, R. Activation of abl family kinases in solid tumors. Genes Cancer 3, 414-425 (2012
21. Srinivasan, D. & Plattner, R. Activation of Abl tyrosine kinases promotes invasion of aggressive breast cancer cells. Cancer Res 66, 5648-5655 (2006
22. Lin, J. et al. Oncogenic activation of c-Abl in non-small cell lung cancer cells lacking FUS1 expression: inhibition of c-Abl by the tumor suppressor gene product Fus1. Oncogene 26, 6989-6996 (2007
23. Suh, Y. et al. Claudin-1 induces epithelial-mesenchymal transition through activation of the c-Abl-ERK signaling pathway in human liver cells. Oncogene 32, 4873-4882 (2013
24. Singer, C. F. et al. Expression of tyrosine kinases in human malignancies as potential targets for kinase-specific inhibitors. Endocr Relat Cancer 11, 861-869 (2004
25. Plattner, R., Kadlec, L., DeMali, K. A., Kazlauskas, A. & Pendergast, A. M. c-Abl is activated by growth factors and Src family kinases and has a role in the cellular response to PDGF. Genes Dev 13, 2400-2411 (1999
26. Tanos, B. & Pendergast, A. M. Abl tyrosine kinase regulates endocytosis of the epidermal growth factor receptor. J Biol Chem 281, 32714-32723 (2006
27. Pendergast, A. M. et al. BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell 75, 175-185 (1993
28. Renshaw, M. W., Lea-Chou, E. & Wang, J. Y. Rac is required for v-Abl tyrosine kinase to activate mitogenesis. Curr Biol 6, 76-83 (1996
29. Talpaz, M. et al. Dasatinib in imatinib-resistant Philadelphia chromosomepositive leukemias. N Engl J Med 354, 2531-2541 (2006
30. Johnson, F. M. et al. Phase II study of dasatinib in patients with advanced nonsmall-cell lung cancer. J Clin Oncol 28, 4609-4615 (2010
31. Johnson, F. M., Saigal, B., Talpaz, M. & Donato, N. J. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Clin Cancer Res 11, 6924-6932 (2005
32. Nagaraj, N. S., Smith, J. J., Revetta, F., Washington, M. K. & Merchant, N. B. Targeted inhibition of SRC kinase signaling attenuates pancreatic tumorigenesis. Mol Cancer Ther 9, 2322-2332 (2010
33. Xiao, J., Lin, H., Luo, X. & Wang, Z. miR-605 joins p53 network to form a p53:miR-605:Mdm2 positive feedback loop in response to stress. EMBOJ 30, 5021 (2011
34. Zhang, J. F. et al. Primate-specific microRNA-637 inhibits tumorigenesis in hepatocellular carcinoma by disrupting signal transducer and activator of transcription 3 signaling. Hepatology 54, 2137-2148 (2011
35. Perdomo, C. et al. MicroRNA 4423 is a primate-specific regulator of airway epithelial cell differentiation and lung carcinogenesis. Proc Natl Acad Sci U S A 110, 18946-51 (2013
36. Mor, E. & Shomron, N. Species-specific microRNA regulation influences phenotypic variability: perspectives on species-specific microRNA regulation. Bioessays 35, 881-888 (2013
37. Soomro, I. N., Holmes, J. & Whimster, W. F. Predicting prognosis in lung cancer: use of proliferationmarker, Ki67 monoclonal antibody. J Pak Med Assoc 48, 66-69 (1998